The lack of predictors for rapid progression in prostate cancer patients receiving sipuleucel-T

Cancers

Volumn 5, Issue 2, 2013, Pages 511-518

  Ng, Laura ^a   Heck, Wendy ^a   Lavsa, Stacey ^a   Crowther, David ^a   Atkinson, Brad ^a   Xiao, Lianchun ^a   Araujo, John ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Immunotherapy; Metastasis; Progression; Prostate cancer; Sipuleucel T

Indexed keywords

ANTIANDROGEN; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; INFUSION RELATED REACTION; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

EID: 84878187265     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers5020511     Document Type: Article

References (13)

1. Jemal A., Bray F., Center MM., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
2. Mohler, J.L.; Armstrong, A.J.; Bahnson, R.R.; Boston, B.; Busby, J.E.; D'Amico, A.V.; Eastham, J.A.; Enke, C.A.; Farrington, T.; Higano, C.S.; et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J. Natl. Compr. Cancer Netw. 2012, 10, 1081-1087.
3. Higano, C.S.; Schellhammer, P.F.; Small, E.J.; Burch, P.A.; Nemunaitis, J.; Yuh, L.; Provost, N.; Frohlich, M.W. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115, 3670-3679.
4. Small, E.J.; Schellhammer, P.F.; Higano, C.S.; Redfern, C.H.; Nemunaitis, J.J.; Valone, F.H.; Verjee, S.S.; Jones, L.A.; Hershberg, R.M. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 2006, 24, 3089-3094.
5. Burch, P.A.; Croghan, G.A.; Gastineau, D.A.; Jones, L.A.; Kaur, J.S.; Kylstra, J.W.; Richardson, R.L.; Valone, F.H.; Vuk-Pavlovic, S. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004, 60, 197-204.
6. Plosker, G.L. Sipuleucel-T: In metastatic castration-resistant prostate cancer. Drugs 2011, 71, 101-108.
7. Dendreon Corporation. Provenge [package insert]; Seattle, WA, USA, 2010.
8. Sheikh, N.A.; Jones, L.A. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol. Immunother. 2008, 57, 1381-1390.
9. Small, E.J.; Fratesi, P.; Reese, D.M.; Strang, G.; Laus, R.; Peshwa, M.V.; Valone, F.H. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 2000, 18, 3894-3903.
10. Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2010, 363, 411-422.
11. Lerner, S.E.; Blute, M.L.; Bergstralh, E.J.; Bostwick, D.G.; Eickholt, J.T.; Zincke, H. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J. Urol. 1996, 156, 137-143.
12. O'Shaughnessy, M.W.C.; Ziegelmann, M.; Konety, B.; Jha, G. Sipuleucel-T immunotherapy in clinical practice: Patient characteristics, tolerability, and survival. J. Clin. Oncol. 2012, 30, e15211.
13. Beer, T.M.; Bernstein, G.T.; Corman, J.M.; Glode, L.M.; Hall, S.J.; Poll, W.L.; Schellhammer, P.F.; Jones, L.A.; Xu, Y.; Kylstra, J.W.; et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin. Cancer Res. 2011, 17, 4558-4567.